Characteristic | All patients (n = 25) |
---|---|
Age, year (range) | 49 (30–72) |
Gender: male, no. (%) | 11 (44) |
Race | |
Caucasian, no. (%) | 22 (88) |
Asian, no. (%) | 1 (4) |
Black, no. (%) | 0 (0) |
Latino/Hispanic, no. (%) | 1 (4) |
Other, no. (%) | 1 (4) |
Diagnosis | |
Glioblastoma, no. (%) | 13 (52) |
Anaplastic astrocytoma, no. (%) | 7 (28) |
Anaplastic oligodendroglioma, no. (%) | 2 (8) |
Unspecified high grade glioma, no. (%) | 2 (8) |
Gliosarcoma, no. (%) | 1 (4) |
Performance status, KPS (range) | 80 (50–100) |
Number of prior therapies, median (range) | 4 (1–9) |
Previously received bevacizumab, no. (%) | 19 (76) |
MGMT status | |
Methylated, no. (%) | 4 (16) |
Unmethylated, no. (%) | 12 (48) |
Unknown, no. (%) | 9 (36) |
IDH1 Status | |
IDH1 Mutated, no. (%) | 10 (40) |
IDH1 Wild Type, no. (%) | 9 (36) |
Unknown, no. (%) | 6 (24) |
Number of mutations by MSK-Impact, median (range) | 7 (3–58) |
PD-1 inhibitor | |
Pembrolizumab, no. (%) | 25 (100) |
Number of doses administered, median (range) | 3 (1–14) |
Concomitant therapy | |
Pembrolizumab monotherapy, no. (%) | 6 (24) |
Bevacizumab, no. (%) | 17 (68) |
Cytotoxic chemotherapy + bevacizumab, no. (%) | 2 (8) |
Receiving dexamethasone at time of first dose, no. (%) | 14 (56%) |